Professor Ngs research contributions to AOD-9604 development include: Synthesis and characterization of the modified C-terminal growth hormone fragment with enhanced stability Design of the tyrosine N-terminal modification to improve peptide stability and half-life Preclinical studies demonstrating lipolytic effects in obese animal models Advancement of the peptide through multiple phases of clinical development Investigation of mechanisms underlying beta-3-adrenergic receptor modulation His work established the foundation for understanding peptide-based approaches to metabolic regulation, though clinical translation ultimately proved unsuccessful
But whats getting the spotlight right now are more than a dozen unapproved peptide drugs that, back in September 2023, the FDA added to its Category 2 Bulk Substances listthats a list of substances that the FDA says pose significant safety risks and are not eligible for compounding without further research
It says nothing about whether the thing works, or whether it's safe
One milligram kept most of the 2.4 mg weight effect in a diabetes trial, and 0.5 mg has years of use behind it. Small real-world series also suggest that reduced-frequency dosing can hold a plateau
Ill finish the 30 day supply but not looking like its going to work for me
Patients already on a stable GLP-1 protocol who want metabolic support during their fat-loss phase tend to do well adding MOTS-C two or three times per week
